{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:30:20Z","timestamp":1740148220913,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03494-5","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T09:45:49Z","timestamp":1717062349000},"page":"3100-3115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells"],"prefix":"10.1007","volume":"26","author":[{"given":"Xiangkai","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhong","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenrui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9778-2787","authenticated-orcid":false,"given":"Lei","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"issue":"3","key":"3494_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3494_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105815","volume":"162","author":"J Heng","year":"2021","unstructured":"Heng J, Tang Q, Chen X, Bao J, Deng J, Chen Y, et al. Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. Eur J Pharm Sci. 2021;162: 105815.","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"3494_CR3","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3390\/genes13081499","volume":"13","author":"R Abdelmaksoud-Dammak","year":"2022","unstructured":"Abdelmaksoud-Dammak R, Ammous-Boukhris N, Saadallah-Kallel A, Charfi S, Khemiri S, Khemakhem R, et al. Predominance of the rare EGFR mutation p.L861Q in Tunisian patients with non-small cell lung carcinoma. Genes (Basel). 2022;13(8):1499.","journal-title":"Genes (Basel)."},{"key":"3494_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105583","volume":"167","author":"RF Dong","year":"2021","unstructured":"Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research. Pharmacol Res. 2021;167: 105583.","journal-title":"Pharmacol Res"},{"key":"3494_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","volume":"61","author":"PT Harrison","year":"2020","unstructured":"Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167\u201379.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"3494_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15(1):173.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"3494_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3892\/ijo.2021.5270","volume":"59","author":"J He","year":"2021","unstructured":"He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (review). Int J Oncol. 2021;59(5):90.","journal-title":"Int J Oncol"},{"issue":"6","key":"3494_CR8","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/ijms20061431","volume":"20","author":"A Russo","year":"2019","unstructured":"Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M, Adamo V. Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario. Int J Mol Sci. 2019;20(6):1431.","journal-title":"Int J Mol Sci"},{"issue":"945","key":"3494_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175571","volume":"15","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li Y, Han Y, Li M, Li X, Fan F, et al. Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor. Eur J Pharmacol. 2023;15(945): 175571.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"3494_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/14656566.2022.2050213","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Wu L. An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer. Expert Opin Pharmacother. 2022;23(6):647\u201352.","journal-title":"Expert Opin Pharmacother"},{"key":"3494_CR11","doi-asserted-by":"publisher","first-page":"204062232211257","DOI":"10.1177\/20406223221125706","volume":"13","author":"C Chen","year":"2022","unstructured":"Chen C, Zhang C, Lin H, Liu Q, Wu L, Zhou C, et al. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis. Ther Adv Chronic Dis. 2022;13:20406223221125704.","journal-title":"Ther Adv Chronic Dis."},{"issue":"4","key":"3494_CR12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s10637-021-01071-z","volume":"39","author":"YT Zhu","year":"2021","unstructured":"Zhu YT, Zhang YF, Jiang JF, Yang Y, Guo LX, Bao JJ, et al. Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers. Investig New Drugs. 2021;39(4):1011\u20138.","journal-title":"Investig New Drugs."},{"issue":"14","key":"3494_CR13","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.3390\/molecules27144474","volume":"27","author":"Y Li","year":"2022","unstructured":"Li Y, Meng L, Ma Y, Xing X, Guo C, Dong Z. Determination of osimertinib, aumolertinib, and furmonertinib in human plasma for therapeutic drug monitoring by UPLC-MS\/MS. Molecules. 2022;27(14):4474.","journal-title":"Molecules"},{"key":"3494_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.trsl.2022.11.002","volume":"255","author":"L An","year":"2023","unstructured":"An L, Wang Y, Wu G, Wang Z, Shi Z, Liu C, et al. Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors. Transl Res. 2023;255:14\u201325.","journal-title":"Transl Res"},{"key":"3494_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116385","volume":"461","author":"Y Wang","year":"2023","unstructured":"Wang Y, Liu Q, Chu C, Li L, Wang Z, Wu G, et al. Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation. Toxicol Appl Pharmacol. 2023;461: 116385.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"19","key":"3494_CR16","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1021\/acs.biochem.2c00384","volume":"61","author":"A Wagner","year":"2022","unstructured":"Wagner A, Galicia-Andres E, Teufl M, Gold L, Obinger C, Sykacek P, et al. Identification of activating mutations in the transmembrane and extracellular domains of EGFR. Biochemistry. 2022;61(19):2049\u201362.","journal-title":"Biochemistry"},{"issue":"3","key":"3494_CR17","doi-asserted-by":"publisher","first-page":"302","DOI":"10.21037\/tlcr.2019.04.12","volume":"8","author":"T Zhang","year":"2019","unstructured":"Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res. 2019;8(3):302\u201316.","journal-title":"Transl Lung Cancer Res."},{"key":"3494_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-1-4939-1862-1_10","volume":"1239","author":"L Cong","year":"2015","unstructured":"Cong L, Zhang F. Genome engineering using CRISPR-Cas9 system. Methods Mol Biol. 2015;1239:197\u2013217.","journal-title":"Methods Mol Biol"},{"issue":"9","key":"3494_CR19","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","volume":"20","author":"M Ranson","year":"2002","unstructured":"Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002;20(9):2240\u201350.","journal-title":"J Clin Oncol"},{"key":"3494_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.06.032","volume":"176","author":"X Liu","year":"2019","unstructured":"Liu X, Li W, Zhang Y, Jiang Y, Zhao Q, Zhong D. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2019;176: 112735.","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"3494_CR21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/jcph.1042","volume":"58","author":"H Zhao","year":"2018","unstructured":"Zhao H, Cao J, Chang J, Zhang Z, Yang L, Wang J, et al. Pharmacokinetics of osimertinib in Chinese patients with advanced NSCLC: a phase 1 study. J Clin Pharmacol. 2018;58(4):504\u201313.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"3494_CR22","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40262-013-0091-4","volume":"52","author":"S Wind","year":"2013","unstructured":"Wind S, Schmid M, Erhardt J, Goeldner RG, Stopfer P. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet. 2013;52(12):1101\u20139.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3494_CR23","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41401-021-00710-8","volume":"43","author":"L Liu","year":"2022","unstructured":"Liu L, Li W, Yang L, Guo ZT, Xue H, Xie NJ, et al. Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers. Acta Pharmacol Sin. 2022;43(4):1082\u201390.","journal-title":"Acta Pharmacol Sin"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03494-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03494-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03494-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:38:22Z","timestamp":1731587902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03494-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3494"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03494-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"assertion":[{"value":"1 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}